Navigation Links
Results of the DEB-AMI Trial reported at TCT 2011
Date:11/10/2011

SAN FRANCISCO, CA NOVEMBER 10, 2011 A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting stents (DES) found that the drug-eluting balloon group did not meet the primary endpoint of reduced late lumen loss. Results of the DEB-AMI (Drug Eluting Balloon in Acute Myocardial Infarction) trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Concerns regarding the safety of DES in ST-segment elevated acute myocardial infarctions (STEMI) continue to exist, including the risk of stent thrombosis. The use of drug-eluting balloons in angioplasty show potential as an alternative to treat STEMI.

In this randomized, international two-center, single-blinded three-arm study, patients were randomly assigned (ratio 1:1:1) to one of the following treatment groups: DEB plus BMS (n=50); BMS (n=50); or DES (n=49) after successful thrombus aspiration.

All patients underwent stenting with an identical stent platform. The primary endpoint was six- month angiographic late lumen loss. Secondary end points were six-month binary restenosis, stent malapposition and re-endothelialization assessed by OCT, endothelial function assessed through acetylcholine testing, and major adverse cardiac events (MACE: death, myocardial infarction, target vessel revascularization).

Late lumen loss at six months was as follows:

  • DEB+BMS: 0.640.56
  • BMS: 0.780.59
  • DES: 0.210.32

The rates of major adverse cardiac events were as follows:

  • DEB+BMS: 10 (20.0%)
  • BMS: 12 (23.5%)
  • DES: 2 (4.1%)

"Results of the DEB-AMI trial indicate that drug-eluting stents induce more pronounced morphological changes (compared to drug-eluting balloons), resulting in superior angiographical and clinical outcomes with respect to bare metal stents and drug-eluting stents," said Pieter R. Stella, MD, PhD, the lead investigator of the trial. Dr. Stella is Director of the Heart Catheterization Laboratories and Director of Clinical Cardiovascular Research at the University Medical Centre Utrecht in The Netherlands.

Researchers noted however, that experience of the operators and discrepancies between the two trial sites may have impacted the findings.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the RIFLE STEACS clinical trial reported at TCT 2011
2. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
3. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
4. Combination epigenetic therapy clinical trial results
5. Results of the PARIS registry Reported at TCT 2011
6. Results of the TRIGGER-PCI trial reported at TCT 2011
7. Results of rapid gene trial reported at TCT 2011
8. Results of the BRIDGE trial reported at TCT 2011
9. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
10. Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests
11. E-counselling shows dramatic results in lowering blood pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s ... It's A Boy! God’s Gift: A Story of Love” is the creation of published ... Published by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a ...
(Date:8/18/2017)... New York (PRWEB) , ... ... ... Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light logistics ... it has entered into a definitive agreement to purchase Unitrans International Corporation, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an ... an educational webinar, they will present the line of epMotion automated liquid handling ... easy you can automate everyday pipetting tasks. , Ideal for scientists and lab ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, ... communities in east Texas, is launching a regional charity effort to provide publicity ... 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based insurance ... is spearheading a regional charity campaign organized to provide support to Christina Upchurch and ... this year, Christina and her children returned from out of town to find her ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
(Date:8/2/2017)... 2017 CaryRx, a next-generation full-service pharmacy, has announced ... patients in the Washington D.C. metropolitan ... providing delivery of medications through the convenience of its patient-friendly ... delivered within one hour to any location in D.C. ... this invaluable service to Washington D.C. ," says ...
(Date:7/31/2017)... , July 31, 2017 7D Surgical, developer ... Medical has purchased the 7D Surgical System to support its ... Washington D.C. and Virginia.  7D Surgical has ... for many of the premier medical facilities within those markets. ... ...
Breaking Medicine Technology: